bioAffinity Technologies/$BIAF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About bioAffinity Technologies
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Ticker
$BIAF
Sector
Primary listing
Employees
57
Headquarters
Website
BIAF Metrics
BasicAdvanced
$11m
-
-$8.66
2.44
-
Price and volume
Market cap
$11m
Beta
2.44
52-week high
$7.29
52-week low
$0.69
Average daily volume
4.6m
Financial strength
Current ratio
2.603
Quick ratio
2.406
Long term debt to equity
10.676
Total debt to equity
15.95
Interest coverage (TTM)
-238.27%
Profitability
EBITDA (TTM)
-10.064
Gross margin (TTM)
31.40%
Net profit margin (TTM)
-241.96%
Operating margin (TTM)
-171.58%
Effective tax rate (TTM)
-0.30%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-75.63%
Return on equity (TTM)
-301.83%
Valuation
Price to revenue (TTM)
0.694
Price to book
1.53
Price to tangible book (TTM)
2.17
Price to free cash flow (TTM)
-0.456
Free cash flow yield (TTM)
-219.54%
Free cash flow per share (TTM)
-5.456
Growth
Revenue change (TTM)
-34.18%
Earnings per share change (TTM)
-61.27%
3-year revenue growth (CAGR)
986.60%
3-year earnings per share growth (CAGR)
-45.79%
BIAF News
AllArticlesVideos
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
Business Wire·3 days ago
New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
Business Wire·2 weeks ago
New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for bioAffinity Technologies stock?
bioAffinity Technologies (BIAF) has a market cap of $11M as of May 01, 2026.
What is the P/E ratio for bioAffinity Technologies stock?
The price to earnings (P/E) ratio for bioAffinity Technologies (BIAF) stock is 0 as of May 01, 2026.
Does bioAffinity Technologies stock pay dividends?
No, bioAffinity Technologies (BIAF) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next bioAffinity Technologies dividend payment date?
bioAffinity Technologies (BIAF) stock does not pay dividends to its shareholders.
What is the beta indicator for bioAffinity Technologies?
bioAffinity Technologies (BIAF) has a beta rating of 2.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.